An assessment of the toxicity of parenteral treatment with copper EDTA and copper heptonate in sheep

Simple item page
dc.contributor.authorVan Niekerk F.E.
dc.contributor.authorCloete S.W.P.
dc.contributor.authorCoetzer W.A.
dc.contributor.authorDu Plessis S.S.
dc.contributor.authorWellington A.C.
dc.contributor.authorSmith W.A.
dc.date.accessioned2011-05-15T15:57:02Z
dc.date.available2011-05-15T15:57:02Z
dc.date.issued1994
dc.description.abstractThe toxicity of 2 parenteral copper (Cu) supplements was investigated. Di-sodium copper ethylene diamino tetra acetate (Cu EDTA) and Cu heptonate were administered to sheep (n = 9) by a single subcutaneous injection at a concentration of 0,2, 1 and 2 mg Cu/kg each (Trial 1). Nine sheep were untreated and served as controls. The same treatments were applied to 2 sheep each (Trial 2) with the addition of 3 mg Cu/kg life body mass as Cu heptonate, and Cu heptonate administered intravenously at rates of 0,2, 0,4 and 0,6 mg Cu/kg live body mass. In Trial 1, 67% of the sheep treated with Cu EDTA at 2 mg Cu/kg live body mass died within 3 to 17 d after treatment, while no mortalities occurred in sheep where Cu heptonate was administered at the same dosage rate and even at 3 mg Cu/kg live body mass (P ≤ 0,01). Post-mortem examination suggested acute Cu toxicity in all cases. Liver Cu concentrations were markedly increased (P ≤ 0,05) by both supplements in groups of 3 treated sheep slaughtered over a 3-month period compared to control animals. The liver Cu concentrations of sheep that succumbed to Cu toxicity were within the normal range of 100 to 450 mg/kg DM. Results from Trial 2 suggested that the 2 sheep treated with 2 mg Cu/kg live body mass as Cu EDTA, experienced a haemolytic crisis between 5 and 11 d after treatment, resulting in the death of one of these sheep. The haemolytic crisis was characterised by a severe decrease in haemoglobin concentration and haematocrit. Sheep treated with Cu heptonate did not show any indications of similar complications, even when given 3 mg Cu/kg live body mass subcutaneously or 0,6 mg Cu/kg live body mass intravenously.
dc.description.versionArticle
dc.identifier.citationJournal of the South African Veterinary Association
dc.identifier.citation65
dc.identifier.citation2
dc.identifier.issn382809
dc.identifier.urihttp://hdl.handle.net/10019.1/10175
dc.subjectcopper complex
dc.subjectcopper edta
dc.subjectcopper heptonate
dc.subjectcuvine
dc.subjectunclassified drug
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectarticle
dc.subjectautopsy
dc.subjectcontrolled study
dc.subjectcopper deficiency
dc.subjecthemolysis
dc.subjectintravenous drug administration
dc.subjectnonhuman
dc.subjectsheep
dc.subjectsubcutaneous drug administration
dc.subjectsupplementation
dc.subjecttoxicity
dc.subjecttoxicity testing
dc.subjectAnimal
dc.subjectComparative Study
dc.subjectCopper
dc.subjectEdetic Acid
dc.subjectFemale
dc.subjectLiver
dc.subjectMale
dc.subjectSheep
dc.subjectSheep Diseases
dc.titleAn assessment of the toxicity of parenteral treatment with copper EDTA and copper heptonate in sheep
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications